Skip to content
naulon

Not checkedNot checked for notices yet.

Pancreatic islet organoids-on-a-chip: how far have we gone?

Jiaxiang Yin, Hao Meng, Jingfang Lin and 3 more

Journal of Nanobiotechnology · 2022

doi:10.1186/s12951-022-01518-2 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Abstract Diabetes mellitus (DM) is a disease caused by dysfunction or disruption of pancreatic islets. The advent and development of microfluidic organoids-on-a-chip platforms have facilitated reproduce of complex and dynamic environment for tissue or organ development and complex disease processes. For the research and treatment of DM, the platforms have been widely used to investigate the physiology and pathophysiology of islets. In this review, we first highlight how pancreatic islet organoids-on-a-chip have improved the reproducibility of stem cell differentiation and organoid culture. We further discuss the efficiency of microfluidics in the functional evaluation of pancreatic islet organoids, such as single-islet-sensitivity detection, long-term real-time monitoring, and automatic glucose adjustment to provide relevant stimulation. Then, we present the applications of islet-on-a-chip technology in disease modeling, drug screening and cell replacement therapy. Finally, we summarize the development and challenges of islet-on-a-chip and discuss the prospects of future research. Graphical Abstract

Abstract licence: CC BY-NC-ND

References93

    40 more references, whose wording the paper’s licence keeps private.

    All 93 references

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.